

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : U.S. Serial Number 10/541,388
Applicant : Rappold-Hoerbrand et al.
Filed : July 1, 2005
TC/A.U. :
Examiner :

Docket No. : 2851-140
Customer No. : 6449
Confirmation No. :

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants submit herewith information that the Office may wish to consider in examination of the subject application. Materials submitted for consideration are listed on the attached form PTO-1449. The references are cited in the specification. Copies of the references are attached.

This statement is being submitted prior the receipt of the first Office Action on the merits. No certification or fee is required.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

By 

Monica Chin Kitts
Reg. No.: 36,105
Attorney for Applicants
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK, PC
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

MCK/cb

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/541,388
				Filing Date	July 1, 2005
				First Named Inventor	Rappold-Hoerbrand et al.
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	1	of	2	Attorney Docket Number	2951-140

NON PATENT LITERATURE DOCUMENTS

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
	1.	Bettencourt, "Brain Natriuretic Peptide (Nesiritide) in the Treatment of Heart Failure," <u>Cardiovascular Drug Reviews</u> , Vol. 20, No. 1, (2002), pp. 27 – 36.		
	2.	Blaschke and Rappold, "SHOX: Growth, Léri-Weill and Turner Syndromes," TEM, Vol. 11, No. 6 (2000), pp. 227-230.		
	3.	Bordenave et al., "Human bone marrow endothelial cells: a new identified source of B-type natriuretic peptide," <u>Peptides</u> 23 (2002), pp. 935-940.		
	4.	Burger M. R., Burger A. J. (2001) BNP in decompensated heart failure: diagnostic, prognostic and therapeutic potential. Curr. Opin. Investig. Drugs, 2(7): 929-935.(Abstract)		
	5.	Carel et al., "Near Normalization of Final Height with Adapted Doses of Growth Hormone in Turner's Syndrome," <u>J. Clinical Endocrinology & Metabolism</u> , Vol. 83, No. 5 (1998), pp. 1462-1466.		
	6.	Cho, Y., Somer, B. G. and Amatya A. (1999) Natriuretic peptides and their therapeutic potential. Heart Dis. Nov-Dec; 1 (5): 305-328. (Abstract)		
	7.	Chusho et al., "Genetic Models Reveal That Brain Natriuretic Peptide Can Signal through Different Tissue-Specific Receptor-Mediated Pathways*," <u>Endocrinology</u> , Vol. 141, No. 10 (2000), pp. 3807-3813.		
	8.	Chusho et al., "Dwarfism and early death in mice lacking C-type natriuretic peptide," PNAS, Vol. 98, No. 7 (March 2001), pp. 4016-4021.		
	9.	Dhingra et al., "Brain Natriuretic Peptide: Role in Cardiovascular and Volume Homeostasis," <u>Seminars In Nephrology</u> , Vol. 22, No. 5 (September 2002), pp. 423-437.		
	10.	Ellison et al., "PHOG, a candidate gene for involvement in the short stature of Turner syndrome," <u>Human Molecular Genetics</u> , Vol. 6, No. 8 (1997), pp. 1341-1347.		
	11.	Ogawa, Y., Itoh, H., Nakagawa, O., Shirakami, G., Tamura, N., Yoshimasa, T., Nagata, K., Yoshida, N. and Nakao, K. (1995) Characterization of the 5'-flanking region and chromosomal assignment of the human brain natriuretic peptide gene. J. Mol. Med. 1995 Sep; 73 (9): 457-463. (Abstract)		
	12.	Rappold et al., "Deletions of the Homeobox Gene SHOX (Short Stature Homeobox) Are an Important Cause of Growth Failure in Children with Short Stature," J. Clinical Endocrinology & Metabolism, 87(3) (March 2002), pp. 1402-1406.		
	13.	Rao et al., "Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome," <u>Nature Genetics</u> , Vol. 16, (May 1997), pp. 54-63.		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	10/541,388
				Filing Date	July 1, 2005
				First Named Inventor	Rappold-Hoerbrand et al.
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	2	of	2	Attorney Docket Number	2951-140

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	14.	Rao et al., "The Leri-Weill and Turner syndrome homeobox gene SHOX encodes a cell-type specific transcriptional activator", HUMAN MOLECULAR GENETICS, 2001, vol. 10, no. 26, 3083-3091.	
	15.	Rosenfeld et al., "Recommendations for Diagnosis, Treatment, and Management of Individuals with Turner Syndrome," <u>Endocrinologist</u> , Vol. 4, No. 5 (1994), pp. 351-358.	
	16.	Rosenfeld, et al., "Growth hormone therapy of Turner's syndrome: Beneficial effect on adult height," <u>J. of Pediatrics</u> , Vol. 132, No. 2 (Feb. 1988), pp. 319-324.	
	18.	Sas et al., "Normalization of Height in Girls with Turner Syndrome after Long-Term Growth Hormone Treatment: Results of a Randomized Dose-Response Trial*," <u>J. Clinical Endocrinology & Metabolism</u> , Vol. 84, No. 12 (1999), pp. 4607-4612.	
	19	Seilhamer, J.J., Arfsten, A., Miller, J.A., Lundquist, P., Scarborough, R.M., Lewicki, J.A. and Porter, J.G. (1989) Human and canine gene homologs of porcine brain natriuretic peptide. <u>Biochem. Biophys. Res. Commun.</u> 1989 Dec 15; 165(2): 650-8. (Abstract)	
	20.	Suda et al., "Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95 (1998), pp. 2337-2342.	
	21.	Weinmann and Farnham, "Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation," <u>Methods</u> 26 (2002), pp. 37-47.	
	22.	Wilson, D., Sheng, G., Lecuit, T., Dostatni, N. and Desplan, C. (1993) Cooperative dimerization of paired class homeodomains on DNA. <u>Genes & Dev.</u> , Vol. 7, 2120-2134. (Abstract)	
	23.	Wilson, D. S., Guenther, B., Desplan, C. and Kuriyan, J. (1995) High resolution crystal structure of a paired (pax) class cooperative homeodomain dimer on DNA. <u>Cell</u> , 82: 709-719.	

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.